For example, Mitrofanova et al. conducted a study using GEMMs to correlate expression levels of prostate cancer driver mutations such as FOXM1 and CENPF to those in human prostate cancer databases to predict drug response by targeting these specific mutational drivers [123]. This evidence concerns the gene FOXM1 and prostate carcinoma.